136 related articles for article (PubMed ID: 8386983)
1. The role of topoisomerase II alpha and beta in drug resistance.
Hochhauser D; Harris AL
Cancer Treat Rev; 1993 Apr; 19(2):181-94. PubMed ID: 8386983
[No Abstract] [Full Text] [Related]
2. [Multidrug resistance of neoplastic cells--facts and hypotheses].
Grzelakowska-Sztabert B
Postepy Biochem; 1989; 35(4):513-41. PubMed ID: 2577370
[No Abstract] [Full Text] [Related]
3. The role of DNA topoisomerases II in drug resistance.
Alton PA; Harris AL
Br J Haematol; 1993 Oct; 85(2):241-5. PubMed ID: 8280597
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance associated with altered DNA topoisomerase II.
Beck WT; Danks MK; Wolverton JS; Kim R; Chen M
Adv Enzyme Regul; 1993; 33():113-27. PubMed ID: 8395133
[No Abstract] [Full Text] [Related]
6. Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II.
Deffie AM; McPherson JP; Gupta RS; Hedley DW; Goldenberg GJ
Biochem Cell Biol; 1992 May; 70(5):354-64. PubMed ID: 1353968
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.
Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK
Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
Harker WG; Slade DL; Drake FH; Parr RL
Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
[TBL] [Abstract][Full Text] [Related]
9. DNA-topoisomerase I and II: biologic features and their role in drug resistance.
Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R
Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050
[No Abstract] [Full Text] [Related]
10. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
Ishida R; Andoh T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
[TBL] [Abstract][Full Text] [Related]
11. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Beck WT; Danks MK
Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
[TBL] [Abstract][Full Text] [Related]
13. [Atypical MDR].
Yokomizo A; Taniguchi K; Hasegawa S; Abe T; Kubo T; Makino Y; Wada M; Kohno K; Kuwano M
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1123-9. PubMed ID: 7913311
[TBL] [Abstract][Full Text] [Related]
14. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
16. The role of topoisomerase II in drug resistance.
De Isabella P; Capranico G; Zunino F
Life Sci; 1991; 48(23):2195-205. PubMed ID: 1646358
[TBL] [Abstract][Full Text] [Related]
17. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.
Brown GA; McPherson JP; Gu L; Hedley DW; Toso R; Deuchars KL; Freedman MH; Goldenberg GJ
Cancer Res; 1995 Jan; 55(1):78-82. PubMed ID: 7805045
[TBL] [Abstract][Full Text] [Related]
18. Circumvention of atypical multidrug resistance with tumor necrosis factor.
Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Stahl M; Kasimir-Bauer S; Harstrick A
Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II in multiple drug resistance.
Hofmann GA; Mattern MR
Cytotechnology; 1993; 12(1-3):137-54. PubMed ID: 7765323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
